Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

A central nervous system specific mouse model for thanatophoric dysplasia type II.

Lin T, Sandusky SB, Xue H, Fishbein KW, Spencer RG, Rao MS, Francomano CA.

Hum Mol Genet. 2003 Nov 1;12(21):2863-71. Epub 2003 Sep 9.

PMID:
12966031
2.

Highly activated Fgfr3 with the K644M mutation causes prolonged survival in severe dwarf mice.

Iwata T, Li CL, Deng CX, Francomano CA.

Hum Mol Genet. 2001 Jun 1;10(12):1255-64.

PMID:
11406607
3.

Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism.

Su WC, Kitagawa M, Xue N, Xie B, Garofalo S, Cho J, Deng C, Horton WA, Fu XY.

Nature. 1997 Mar 20;386(6622):288-92.

PMID:
9069288
5.

Constitutively activated FGFR3 mutants signal through PLCgamma-dependent and -independent pathways for hematopoietic transformation.

Chen J, Williams IR, Lee BH, Duclos N, Huntly BJ, Donoghue DJ, Gilliland DG.

Blood. 2005 Jul 1;106(1):328-37. Epub 2005 Mar 22.

6.

A neonatal lethal mutation in FGFR3 uncouples proliferation and differentiation of growth plate chondrocytes in embryos.

Iwata T, Chen L, Li C, Ovchinnikov DA, Behringer RR, Francomano CA, Deng CX.

Hum Mol Genet. 2000 Jul 1;9(11):1603-13.

PMID:
10861287
7.

Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4.

Hart KC, Robertson SC, Kanemitsu MY, Meyer AN, Tynan JA, Donoghue DJ.

Oncogene. 2000 Jul 6;19(29):3309-20.

8.
9.
11.
12.

Fibroblast growth factor receptor 3 signaling regulates the onset of oligodendrocyte terminal differentiation.

Oh LY, Denninger A, Colvin JS, Vyas A, Tole S, Ornitz DM, Bansal R.

J Neurosci. 2003 Feb 1;23(3):883-94.

13.

Improved diagnosis of a common mutation (R248C) in the human growth factor receptor 3 (FGFR3) gene that causes type I Thanatophoric dysplasia.

Simsek M, Al-Gazali L, Al-Mjeni R, Bayoumi R.

Clin Biochem. 2003 Mar;36(2):151-3. No abstract available.

PMID:
12633765
14.

Transient dimerization and interaction with ERGIC-53 occur in the fibroblast growth factor receptor 3 early secretory pathway.

Lievens PM, De Servi B, Garofalo S, Lunstrum GP, Horton WA, Liboi E.

Int J Biochem Cell Biol. 2008;40(11):2649-59. doi: 10.1016/j.biocel.2008.05.017. Epub 2008 Jun 5.

PMID:
18577465
15.

A novel FGFR3-binding peptide inhibits FGFR3 signaling and reverses the lethal phenotype of mice mimicking human thanatophoric dysplasia.

Jin M, Yu Y, Qi H, Xie Y, Su N, Wang X, Tan Q, Luo F, Zhu Y, Wang Q, Du X, Xian CJ, Liu P, Huang H, Shen Y, Deng CX, Chen D, Chen L.

Hum Mol Genet. 2012 Dec 15;21(26):5443-55. doi: 10.1093/hmg/dds390. Epub 2012 Sep 26.

16.
17.
18.

Fgfr3 expression by astrocytes and their precursors: evidence that astrocytes and oligodendrocytes originate in distinct neuroepithelial domains.

Pringle NP, Yu WP, Howell M, Colvin JS, Ornitz DM, Richardson WD.

Development. 2003 Jan;130(1):93-102.

19.

Signalling by fibroblast growth factor receptor 3 and parathyroid hormone-related peptide coordinate cartilage and bone development.

Amizuka N, Davidson D, Liu H, Valverde-Franco G, Chai S, Maeda T, Ozawa H, Hammond V, Ornitz DM, Goltzman D, Henderson JE.

Bone. 2004 Jan;34(1):13-25.

PMID:
14751559

Supplemental Content

Support Center